Trials / Completed
CompletedNCT02424019
Phase 4 IOP Signals Associated With ILUVIEN®
A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Alimera Sciences · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
Detailed description
The specific objectives include the study of intraocular pressure (IOP) related data in patients who received ILUVIEN and how it relates to the patient's experiences following prior treatment with a course of corticosteroid which did not result in a clinically significant IOP elevation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ILUVIEN 0.19 MG |
Timeline
- Start date
- 2015-05-06
- Primary completion
- 2020-07-29
- Completion
- 2020-07-31
- First posted
- 2015-04-22
- Last updated
- 2022-01-11
Locations
41 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02424019. Inclusion in this directory is not an endorsement.